Why the study?
Residual neuromuscular block remains a significant perioperative safety concern and is still widely under-recognized by perioperative healthcare professionals.
Does quantitative neuromuscular monitoring and reversal reduce the risk of residual neuromuscular block in patients undergoing general anesthesia?
Does quantitative neuromuscular monitoring and reversal reduce the risk of residual neuromuscular block in patients undergoing general anesthesia?
Answers are grounded in this paper and cite their sources.
Residual neuromuscular block remains a significant safety concern, and quantitative monitoring combined with reversal agents like sugammadex is recommended to reduce its incidence.
Residual neuromuscular block (RNMB) remains a significant safety concern for patients throughout the perioperative period and is still widely under-recognized by perioperative healthcare professionals. Current literature suggests an association between RNMB and an increased risk of postoperative pulmonary complications, a prolonged length of stay in the post anesthesia care unit (PACU), and decreased patient satisfaction. The 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade provide guidance for the use of quantitative neuromuscular monitoring coupled with neuromuscular reversal to recognize and reduce the incidence of RNMB. Using sugammadex for the reversal of neuromuscular block as well as quantitative neuromuscular monitoring to quantify the degree of neuromuscular block may significantly reduce the risk of RNMB among patients undergoing general anesthesia. Studies are forthcoming to investigate how using neuromuscular blocking agent reversal with quantitative monitoring of the neuromuscular block may further improve perioperative patient safety.
No takes yet. Share an insight, caveat, or question.
Blum et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: